What’s New in Ontosight® Terminal 1.1 A Complete Guide toRead More
What’s New in Ontosight® Terminal 1.1
Innoplexus and ChemAxon partner to get more out of life science data
Frankfurt, Germany – Budapest, Hungary, September 16, 2019 – Innoplexus announces an official partnership with ChemAxon, getting the most value out from life sciences data. Through the joint venture, Innoplexus will enable big pharma and biotech companies to find and connect information about pharmaceutical compounds from publicly available, or archived enterprise datasets to generate novel ideas.
ChemAxon provides best-in-class solutions in cheminformatics for the chemistry, biotechnology, pharmaceutical, and agrochemical industries. Innoplexus, a global leader in artificial intelligence (AI) and blockchain for the life sciences industry, will leverage one of ChemAxon’s products, ChemLocator, to search all potential, pre-clinical, clinical or marketed drugs in all documents across data assets in Innoplexus product, Ontosight® , to detect industry-relevant signals much earlier than traditional methods.
ChemLocator is a web-based search tool with chemical recognition capabilities that allows users to discover hidden chemical knowledge and extract structures from documents. Combining ChemLocator with Innoplexus computer vision and ontology will accelerate the time to find any chemical or compound using its name or chemical properties or even the structure from unstructured data available.
- ChemLocator offers a significant edge to Ontosight® users by allowing them to discover otherwise-unavailable information in public domains or “forgotten” information in enterprise archives such as competing or novel compounds in the area of interest.
- Connecting disparate information pieces across different public and enterprise documents, ChemLocator-backed Ontosight® accelerates the research by highlight non-obvious findings or discover unexplored whitespaces.
“The 4th Industrial Revolution is changing the world, and we are glad to be partnering with a leading AI company to tackle one of the most exciting challenges in the automated data process. We believe extracting chemical structures from scientific literature and facilitating meaningful questions related to those will leverage the transformation of existing information into novel ideas. We truly believe that our integration with Ontosight® will open up new perspectives for life sciences R&D.” David Jozsef, Product Owner of ChemLocator at ChemAxon.
Vatsal Agarwal, Vice President – Artificial Intelligence & Computational Linguistics at Innoplexus, expressed, “We look forward to integrate ChemLocator into Ontosight® to be able to deliver new possibilities to our clients together.” The decision to partner with ChemAxon was realized out of Innoplexus’ growing dedication to help its users find known as well as previously unknown insights related to biomedical entities and thus, improve how the pharma and biotech industry leverages life sciences data using automation.
The partnership between Innoplexus and ChemAxon will create opportunities to enrich life science research, allowing pharma and biotech companies to be innovative and faster in developing novel therapies.
About ChemAxon
ChemAxon is a chemical and biological software development company that provides solutions for the biotechnology and pharmaceutical industries; and widely used in publishing, flavors, fragrances, petroleum, and fine chemical research. The company offers out-of-the-box solutions for scientists, back- end tools for IT professionals, components to add extra functionality, and integrations to make our technology available from 3rd-party software like Microsoft Excel or KNIME.
Featured News
Partex and Singapore’s Experimental Drug Development Centre collaborate to bring
Frankfurt, Germany, 3rd June 2024, 9am CET Partex, a leading provider of AI-driven solutions in the pharmaceutical industry, is thrilled to…
Partex Partners with Lupin to Revolutionize Drug Discovery through AI-Driven
Frankfurt, Germany, 23 April 2024 – Partex, a leading provider of AI-driven solutions in the pharmaceutical industry, is thrilled to…
Partex NV announces collaboration with Althea DRF Lifesciences to provide
Frankfurt, Germany; 28 March 2024 – Partex Group, a pioneer in AI-driven drug discovery, announces a collaboration with Althea DRF…
Innovative AI technology in oncology: Partex Group presents results from
During the German Cancer Congress 2024 in Berlin, the companies Innoplexus AG /Amrit AG, companies of Partex N.V., presented the…
Partex NV Forges Collaboration with Sanofi in AI-Based Dossier Enrichment
Frankfurt, Germany; 14 March 2024 Partex Group, a pioneer in AI-driven drug discovery, today announces a collaboration with global pharmaceutical…
Innoplexus and AIO Studien gGmbH are jointly announcing the start
January 02, 2024 – Innoplexus and Amrit AG, members of the Partex NV Group, providers of innovative technology for health…
Strategic partnership announcement: Innoplexus holding company Partex NV is pleased
Exciting News! Anavex Life Sciences and Partex NV Announce Strategic Partnership to Enhance Patient Experience. Anavex Life Sciences Corp. and Partex NV N.V. Group are pleased to announce…
AI supports targeted therapy recommendations fortumor diseases – BMBF funds
The treatment and support of patients with advanced tumor diseases is a complex task involving numerous disciplines. For the interdisciplinary…
Innoplexus and Innovatrix capital partner to bring about new risk-transfer
Artificial Intelligence (AI) pioneer Innoplexus and London based Parametric Insurance start-up, Innovatrix Capital, collaborating upon using AI & Machine Learning…
Innoplexus and Inflection Biosciences enter strategic collaboration based on Artificial
Innoplexus and Inflection Biosciences enter strategic collaboration based on Artificial Intelligence to expedite PIM kinase inhibitor development ESCHBORN, Germany, May 30,…
